Feel Comfortable Sticking With NovoSeven RT Over Sevenfact

Sevenfact will join NovoSeven RT as another recombinant factor VIIa option to control bleeding in certain patients with hemophilia.

Sevenfact is currently approved to treat bleeds of any severity in patients 12 years and up with hemophilia A or B who develop “inhibitors”...antibodies to factor replacements.

Inhibitors can form against factor VIII (Advate, etc) or IX (BeneFix, etc) products...which limit their use to treat bleeding.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote